Consensus Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
72.52 ^USD	-8.05%		-10.94%	+1.54%

Apr. 08	Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	CI
Apr. 03	Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer	CI

Evolution of the average Target Price on Ligand Pharmaceuticals Incorporated

Price target over the last 5 years

History of analyst recommendation changes

eb8fb4299f6b145726df32ab.tyFkPUme4Lj9lrsnkKWKHKsxZfSzZ0Q_Y6icdtx-YIw.8FkrRSb6s-rIu4tlouPYVp4CPbr2Hg9dV5_ID7sIGb-DSRRXEfOT14TF0A~c305f586159f2ebd9a5ab811a8b3901a

Analyst Recommendations on Ligand Pharmaceuticals Incorporated

Investors lower their expectations	Jan. 08
Barclays Cuts Price Target on Ligand Pharmaceuticals to $110 From $120, Maintains Overweight Rating	23-07-25	MT
Roth Capital Boosts Price Target on Ligand Pharmaceuticals to $90 From $85, Maintains Buy Rating	22-12-23	MT
HC Wainwright Adjusts Ligand Pharmaceuticals Price Target to $135 From $310, Maintains Buy Rating	22-10-25	MT
Barclays Adjusts Price Target on Ligand Pharmaceuticals to $150 From $157, Reiterates Overweight Rating	22-10-25	MT
Roth Capital Partners Cuts Price Target on Ligand Pharmaceuticals to $175 From $185, Reiterates Buy Rating	22-09-02	MT
Barclays Adjusts Price Target on Ligand Pharmaceuticals to $157 From $165, Reiterates Overweight Rating	22-07-05	MT
CJS Securities Adjusts Ligand Pharmaceuticals Price Target to $145 From $210, Maintains Market Outperform Rating	22-06-14	MT
Stephens Adjusts Ligand Pharmaceuticals' Price Target to $130 from $153, Keeps Overweight Rating	22-05-16	MT
Benchmark Adjusts Ligand Pharmaceuticals' Price Target to $130 From $180, Reiterates Buy Rating	22-02-22	MT
LIGAND PHARMACEUTICALS INCORPORATED : Barclays Boosts Price Target on Ligand Pharmaceuticals to $180 From $174, Maintains Overweight Rating	21-09-22	MT
LIGAND PHARMACEUTICALS INCORPORATED : Roth Capital Adjusts Price Target on Ligand Pharmaceuticals to $190 From $200, Maintains Buy Rating	21-07-30	MT
LIGAND PHARMACEUTICALS INCORPORATED : Barclays Adjusts Price Target on Ligand Pharmaceuticals to $190 From $198, Maintains Overweight Rating	21-05-04	MT
LIGAND PHARMACEUTICALS INCORPORATED : Stephens Reinstates Ligand Pharmaceuticals at Overweight With $200 Price Target	21-04-14	MT
Treasury Markets Calm, But Investors Anticipate a Rate Rise Soon	21-03-25	DJ
LIGAND PHARMACEUTICALS INCORPORATED : Barclays Adjusts Price Target on Ligand Pharmaceuticals to $198 From $146, Reiterates Overweight Rating	21-02-04	MT
LIGAND PHARMACEUTICALS INCORPORATED : Craig-Hallum Adjusts Price Target on Ligand Pharmaceuticals to $215 From $195, Reiterates Buy Rating	21-02-04	MT
LIGAND PHARMACEUTICALS INCORPORATED : Roth Capital Adjusts Price Target on Ligand Pharmaceuticals to $200 From $195, Maintains Buy Rating	21-02-04	MT
LIGAND PHARMACEUTICALS INCORPORATED : HC Wainwright Adjusts Ligand Pharmaceuticals' Price Target to $310 From $299, Keeps Buy Rating	21-02-04	MT
Berenberg USA Conference	18-05-24	FA
Ligand Pharmaceuticals Incorporated to Receive $10 Million from a Contractually Specified Royalty Rate Buy-Down; Provides Financial Guidance for the Year 2017	17-05-31	CI